-
1
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
3
-
-
77952489873
-
Cervical cancer as a public health issue-what next?
-
Corusić A, Skrgatić L, Mahovlić V, Mandić V, Planinić P and Karadza M: Cervical cancer as a public health issue-what next? Coll Antropol 34: 301-307, 2010.
-
(2010)
Coll Antropol
, vol.34
, pp. 301-307
-
-
Corusić, A.1
Skrgatić, L.2
Mahovlić, V.3
Mandić, V.4
Planinić, P.5
Karadza, M.6
-
4
-
-
67650584040
-
-
Bethesda, MD, USA based on November 2008 SEER data submission, posted to the SEER web site
-
Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG and Edwards B: SEER Cancer Statistics Review, 1975-2006, National Cancer Institute, Bethesda, MD, USA. http://seer.cancer.gov/csr/1975-2006/ based on November 2008 SEER data submission, posted to the SEER web site, 2009.
-
(2009)
SEER Cancer Statistics Review, 1975-2006
-
-
Horner, M.J.1
Ries, L.A.G.2
Krapcho, M.3
Neyman, N.4
Aminou, R.5
Howlader, N.6
Altekruse, S.F.7
Feuer, E.J.8
Huang, L.9
Mariotto, A.10
Miller, B.A.11
Lewis, D.R.12
Eisner, M.P.13
Stinchcomb, D.G.14
Edwards, B.15
-
5
-
-
70749125099
-
Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study
-
Moore DH, Tian C, Monk BJ, Long HJ, Omura GA and Bloss JD: Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 116: 44-49, 2010.
-
(2010)
Gynecol Oncol
, vol.116
, pp. 44-49
-
-
Moore, D.H.1
Tian, C.2
Monk, B.J.3
Long, H.J.4
Omura, G.A.5
Bloss, J.D.6
-
6
-
-
69249104203
-
Cervical cancer therapy: Current, future and anti-angiogensis targeted treatment
-
Willmott LJ and Monk BJ: Cervical cancer therapy: current, future and anti-angiogensis targeted treatment. Expert Rev Anticancer Ther 9: 895-903, 2009.
-
(2009)
Expert Rev Anticancer Ther
, vol.9
, pp. 895-903
-
-
Willmott, L.J.1
Monk, B.J.2
-
7
-
-
73949119408
-
Anti-angiogenesis agents in metastatic or recurrent cervical cancer
-
Monk BJ, Willmott LJ and Sumner DA: Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 116: 181-186, 2010.
-
(2010)
Gynecol Oncol
, vol.116
, pp. 181-186
-
-
Monk, B.J.1
Willmott, L.J.2
Sumner, D.A.3
-
8
-
-
69249184415
-
Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas
-
Fujimoto J: Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas. Anticancer Res 29: 2665-2669, 2009.
-
(2009)
Anticancer Res
, vol.29
, pp. 2665-2669
-
-
Fujimoto, J.1
-
9
-
-
60449083456
-
Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study
-
Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ and Fruehauf JP: Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol 112: 583-589, 2009.
-
(2009)
Gynecol Oncol
, vol.112
, pp. 583-589
-
-
Randall, L.M.1
Monk, B.J.2
Darcy, K.M.3
Tian, C.4
Burger, R.A.5
Liao, S.Y.6
Peters, W.A.7
Stock, R.J.8
Fruehauf, J.P.9
-
10
-
-
38949132628
-
Chemotherapy for advanced, recurrent, and metastatic cervical cancer
-
Moore DH: Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 6: 53-57, 2008.
-
(2008)
J Natl Compr Canc Netw
, vol.6
, pp. 53-57
-
-
Moore, D.H.1
-
11
-
-
70350751574
-
Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin
-
Takano M, Kikuchi Y, Kita T, Goto T, Yoshikawa T, Kato M, Watanabe A, Sasaki N, Miyamoto M, Inoue H and Ohbayashi M: Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin. Onkologie 32: 595-597, 2009.
-
(2009)
Onkologie
, vol.32
, pp. 595-597
-
-
Takano, M.1
Kikuchi, Y.2
Kita, T.3
Goto, T.4
Yoshikawa, T.5
Kato, M.6
Watanabe, A.7
Sasaki, N.8
Miyamoto, M.9
Inoue, H.10
Ohbayashi, M.11
-
12
-
-
33750173608
-
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer
-
DOI 10.1016/j.ygyno.2006.03.023, PII S009082580600254X
-
Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW and Rader JS: Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103: 489-493, 2006. (Pubitemid 44602157)
-
(2006)
Gynecologic Oncology
, vol.103
, Issue.2
, pp. 489-493
-
-
Wright, J.D.1
Viviano, D.2
Powell, M.A.3
Gibb, R.K.4
Mutch, D.G.5
Grigsby, P.W.6
Rader, J.S.7
-
13
-
-
61549141361
-
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
-
Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE and Roman LD: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 27: 1069-1074, 2009.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1069-1074
-
-
Monk, B.J.1
Sill, M.W.2
Burger, R.A.3
Gray, H.J.4
Buekers, T.E.5
Roman, L.D.6
-
14
-
-
50149118998
-
Update on novel therapeutic agents for cervical cancer
-
del Campo JM, Prat A, Gil-Moreno A, Perez J and Parera M: Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 110: S72-76, 2008.
-
(2008)
Gynecol Oncol
, vol.110
-
-
Del Campo, J.M.1
Prat, A.2
Gil-Moreno, A.3
Perez, J.4
Parera, M.5
-
15
-
-
13844294265
-
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer
-
Tan BR and McLeod HL: Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 32: 113-119, 2005.
-
(2005)
Semin Oncol
, vol.32
, pp. 113-119
-
-
Tan, B.R.1
McLeod, H.L.2
-
16
-
-
69349097400
-
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy
-
Ebos JM, Lee CR and Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15: 5020-5025, 2009.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5020-5025
-
-
Ebos, J.M.1
Lee, C.R.2
Kerbel, R.S.3
-
17
-
-
62949129110
-
Intricacies of bevacizumab-induced toxicities and their management
-
Gressett SM and Shah SR: Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43: 490-501, 2009.
-
(2009)
Ann Pharmacother
, vol.43
, pp. 490-501
-
-
Gressett, S.M.1
Shah, S.R.2
-
18
-
-
77951937790
-
Bevacizumab toxicities and their management in ovarian cancer
-
Randall LM and Monk BJ: Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 117: 497-504, 2010.
-
(2010)
Gynecol Oncol
, vol.117
, pp. 497-504
-
-
Randall, L.M.1
Monk, B.J.2
-
19
-
-
77951582589
-
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: A review of health economic evaluations
-
Norum J, Nieder C and Kondo M: Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J Chemother 22: 75-82, 2010.
-
(2010)
J Chemother
, vol.22
, pp. 75-82
-
-
Norum, J.1
Nieder, C.2
Kondo, M.3
-
20
-
-
0036581310
-
Lymphatic vessels and lymphangiogenesis in female cancer: Mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies
-
Review
-
Schoppmann SF, Horvat R and Birner P: Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Oncol Rep 9: 455-460, 2002.
-
(2002)
Oncol Rep
, vol.9
, pp. 455-460
-
-
Schoppmann, S.F.1
Horvat, R.2
Birner, P.3
-
21
-
-
36049037879
-
Correlation of angiogenesis and recurrence-free survival of early stage cervical cancer patients undergoing radical hysterectomy with pelvic lymph node dissection
-
DOI 10.1111/j.1447-0756.2007.00666.x
-
Phoophitphong T, Hanprasertpong J, Dechsukhum C and Geater A: Correlation of angiogenesis and recurrence-free survival of early stage cervical cancer patients undergoing radical hysterectomy with pelvic lymph node dissection. J Obstet Gynaecol Res 33: 840-848, 2007. (Pubitemid 350086518)
-
(2007)
Journal of Obstetrics and Gynaecology Research
, vol.33
, Issue.6
, pp. 840-848
-
-
Phoophitphong, T.1
Hanprasertpong, J.2
Dechsukhum, C.3
Geater, A.4
-
22
-
-
79961199199
-
In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer
-
Landt S, Heidecke H, Korlach S, Reuter C, Schwidde I, Barinoff J, Schmid P, Sehouli J and Kümmel S: In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer. Anticancer Res 31: 2609-2616, 2011.
-
(2011)
Anticancer Res
, vol.31
, pp. 2609-2616
-
-
Landt, S.1
Heidecke, H.2
Korlach, S.3
Reuter, C.4
Schwidde, I.5
Barinoff, J.6
Schmid, P.7
Sehouli, J.8
Kümmel, S.9
-
23
-
-
79961178174
-
The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer
-
Landt S, Heidecke H, Reuter C, Korlach S, Blohmer J-U, Lichtenegger W, Heusner T, Schmid P, Sehouli J, Thill M and Kümmel S: The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer. Anticancer Res 31: 2645-2650, 2011.
-
(2011)
Anticancer Res
, vol.31
, pp. 2645-2650
-
-
Landt, S.1
Heidecke, H.2
Reuter, C.3
Korlach, S.4
Blohmer, J.-U.5
Lichtenegger, W.6
Heusner, T.7
Schmid, P.8
Sehouli, J.9
Thill, M.10
Kümmel, S.11
-
24
-
-
0032937361
-
Angiogenesis in malignancies of the female genital tract
-
Abulafia O, Triest WE and Sherer DM: Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 72: 220-231, 1999.
-
(1999)
Gynecol Oncol 72
, pp. 220-231
-
-
Abulafia, O.1
Triest, W.E.2
Sherer, D.M.3
-
25
-
-
77950690217
-
Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer
-
Carpini JD, Karam AK and Montgomery L: Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13: 43-58, 2010.
-
(2010)
Angiogenesis
, vol.13
, pp. 43-58
-
-
Carpini, J.D.1
Karam, A.K.2
Montgomery, L.3
-
26
-
-
18844479070
-
Uterine cervical carcinoma: Comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival
-
Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, Schonberg SO, Essig M, Vaupel P and van Kaick G: Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of timeintensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 58: 3598-3602, 1998. (Pubitemid 28376557)
-
(1998)
Cancer Research
, vol.58
, Issue.16
, pp. 3598-3602
-
-
Hawighorst, H.1
Knapstein, P.G.2
Knopp, M.V.3
Weikel, W.4
Brix, G.5
Zuna, I.6
Schonberg, S.O.7
Essig, M.8
Vaupel, P.9
Van Kaick, G.10
-
27
-
-
77957751347
-
VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival
-
Kim YH, Kim MA, Park IA, Park WY, Kim JW, Kim SC, Park NH, Song YS and Kang SB: VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival. Gynecol Oncol 119(2): 232-236, 2010.
-
(2010)
Gynecol Oncol
, vol.119
, Issue.2
, pp. 232-236
-
-
Kim, Y.H.1
Kim, M.A.2
Park, I.A.3
Park, W.Y.4
Kim, J.W.5
Kim, S.C.6
Park, N.H.7
Song, Y.S.8
Kang, S.B.9
-
28
-
-
67349233128
-
Expression of endoglin (CD105) in cervical cancer
-
Zijlmans HJ, Fleuren GJ, Hazelbag S, Sier CF, Dreef EJ, Kenter GG and Gorter A: Expression of endoglin (CD105) in cervical cancer. Br J Cancer 100: 1617-1626, 2009.
-
(2009)
Br J Cancer
, vol.100
, pp. 1617-1626
-
-
Zijlmans, H.J.1
Fleuren, G.J.2
Hazelbag, S.3
Sier, C.F.4
Dreef, E.J.5
Kenter, G.G.6
Gorter, A.7
-
29
-
-
33750621551
-
Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers
-
DOI 10.1111/j.1440-1827.2006.02037.x
-
Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T and Tokunaga O: Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 56: 717-723, 2006. (Pubitemid 44691157)
-
(2006)
Pathology International
, vol.56
, Issue.12
, pp. 717-723
-
-
Minhajat, R.1
Mori, D.2
Yamasaki, F.3
Sugita, Y.4
Satoh, T.5
Tokunaga, O.6
-
31
-
-
34247104610
-
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma
-
DOI 10.1309/X6NXYE57DLUE2NQ8
-
El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R and Saad RS: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 127: 572-579, 2007. (Pubitemid 46587470)
-
(2007)
American Journal of Clinical Pathology
, vol.127
, Issue.4
, pp. 572-579
-
-
El-Gohary, Y.M.1
Silverman, J.F.2
Olson, P.R.3
Liu, Y.L.4
Cohen, J.K.5
Miller, R.6
Saad, R.S.7
-
32
-
-
33745068191
-
Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma
-
Yang LY, Lu WQ, Huang GW and Wang W: Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 6: 110, 2006.
-
(2006)
BMC Cancer
, vol.6
, pp. 110
-
-
Yang, L.Y.1
Lu, W.Q.2
Huang, G.W.3
Wang, W.4
-
33
-
-
54849409198
-
Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary
-
Ødegaard E, Davidson B, Engh V, Onsrud M and Staff AC: Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am J Obstet Gynecol 199: 533 e531-538, 2008.
-
(2008)
Am J Obstet Gynecol
, vol.199
-
-
Ødegaard, E.1
Davidson, B.2
Engh, V.3
Onsrud, M.4
Staff, A.C.5
-
34
-
-
34547927931
-
Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma
-
DOI 10.1097/MEG.0b013e3282202bea, PII 0004273720070900000004
-
Yagmur E, Rizk M, Stanzel S, Hellerbrand C, Lammert F, Trautwein C, Wasmuth HE and Gressner AM: Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. Eur J Gastroenterol Hepatol 19: 755-761, 2007. (Pubitemid 47266703)
-
(2007)
European Journal of Gastroenterology and Hepatology
, vol.19
, Issue.9
, pp. 755-761
-
-
Yagmur, E.1
Rizk, M.2
Stanzel, S.3
Hellerbrand, C.4
Lammert, F.5
Trautwein, C.6
Wasmuth, H.E.7
Gressner, A.M.8
-
35
-
-
0031895639
-
Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer
-
Chopra V, Dinh TV and Hannigan EV: Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 16: 152-159, 1998. (Pubitemid 28158437)
-
(1998)
Cancer Investigation
, vol.16
, Issue.3
, pp. 152-159
-
-
Chopra, V.1
Dinh, T.V.2
Hannigan, E.V.3
-
37
-
-
33344472286
-
Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action
-
Folkman J: Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312: 594-607, 2006.
-
(2006)
Exp Cell Res
, vol.312
, pp. 594-607
-
-
Folkman, J.1
-
38
-
-
33644543821
-
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas
-
Gruszka A, Kunert-Radek J, Pawlikowski M and Stepien H: Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas. Pituitary 8: 163-168, 2005.
-
(2005)
Pituitary
, vol.8
, pp. 163-168
-
-
Gruszka, A.1
Kunert-Radek, J.2
Pawlikowski, M.3
Stepien, H.4
-
39
-
-
33748656557
-
Serum endostatin levels in gastric cancer patients: Correlation with clinicopathological parameters
-
Koç M, Göçmen E, Kiliç M, Ozbay M, Oktem M and Tez M: Serum endostatin levels in gastric cancer patients: correlation with clinicopathological parameters. Hepatogastroenterology 53: 616-618, 2006.
-
(2006)
Hepatogastroenterology
, vol.53
, pp. 616-618
-
-
Koç, M.1
Göçmen, E.2
Kiliç, M.3
Ozbay, M.4
Oktem, M.5
Tez, M.6
-
40
-
-
79961185789
-
Progostic significance of angiogenic factors in uterine cervical cancer
-
Landt S, Heidecke H, Jeschke S, Korlach S, Blohmer J-U, Lichtenegger W, Schmid P, Stöblen F, Sehouli J and Kümmel S: Progostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res 31: 2589-2596, 2011.
-
(2011)
Anticancer Res
, vol.31
, pp. 2589-2596
-
-
Landt, S.1
Heidecke, H.2
Jeschke, S.3
Korlach, S.4
Blohmer, J.-U.5
Lichtenegger, W.6
Schmid, P.7
Stöblen, F.8
Sehouli, J.9
Kümmel, S.10
-
42
-
-
33344459620
-
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
-
DOI 10.1038/sj.bjc.6602952
-
Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn HJ, Hamacher J and Boneberg EM: Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94: 524-531, 2006. (Pubitemid 43289756)
-
(2006)
British Journal of Cancer
, vol.94
, Issue.4
, pp. 524-531
-
-
Furstenberger, G.1
Von Moos, R.2
Lucas, R.3
Thurlimann, B.4
Senn, H.-J.5
Hamacher, J.6
Boneberg, E.-M.7
|